CO2017012670A2 - Unidad de dosificación orodispersable que contiene un componente estetrol - Google Patents
Unidad de dosificación orodispersable que contiene un componente estetrolInfo
- Publication number
- CO2017012670A2 CO2017012670A2 CONC2017/0012670A CO2017012670A CO2017012670A2 CO 2017012670 A2 CO2017012670 A2 CO 2017012670A2 CO 2017012670 A CO2017012670 A CO 2017012670A CO 2017012670 A2 CO2017012670 A2 CO 2017012670A2
- Authority
- CO
- Colombia
- Prior art keywords
- estetrol
- weight
- dosage unit
- orodispersible
- dosing unit
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title abstract 7
- 229950009589 estetrol Drugs 0.000 title abstract 6
- 239000007787 solid Substances 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172767 | 2015-06-18 | ||
| PCT/EP2016/064065 WO2016203006A1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible dosage unit containing an estetrol component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012670A2 true CO2017012670A2 (es) | 2018-03-28 |
Family
ID=53496426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012670A CO2017012670A2 (es) | 2015-06-18 | 2017-12-11 | Unidad de dosificación orodispersable que contiene un componente estetrol |
Country Status (42)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012264602B2 (en) | 2011-06-01 | 2017-03-09 | Estetra Srl | Process for the production of estetrol intermediates |
| HUE031809T2 (en) | 2011-06-01 | 2017-08-28 | Estetra Sprl | Process for the preparation of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| BR112017027229B1 (pt) | 2015-06-18 | 2023-12-05 | Estetra Sprl | Grânulos contendo estetrol secos, unidade de dosagem compreendendo grânulos, processo de preparação e seus usos |
| EP3106148B1 (en) | 2015-06-18 | 2018-03-14 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| DK3310346T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| EP4221693A1 (en) * | 2020-09-29 | 2023-08-09 | Millicent Pharma Limited | Orodispersible formulations |
| CA3198547A1 (en) | 2020-11-16 | 2022-05-19 | Mark RIDALL | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CL2021001762A1 (es) * | 2021-07-01 | 2022-01-21 | Univ Pontificia Catolica Chile | Uso del estetrol como tratamiento para la endometriosis |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
| US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
| US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| CA1306950C (en) | 1987-04-10 | 1992-09-01 | Alec D. Keith | Buccal administration of estrogens |
| US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| GB2228412B (en) | 1989-02-28 | 1993-04-14 | Syntex Inc | Nicardipine pharmaceutical composition for parenteral administration |
| JPH03237557A (ja) | 1990-02-14 | 1991-10-23 | Oki Electric Ind Co Ltd | ニューラルネットワークシミュレータ及び計算機システム |
| US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
| JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| WO1996003929A1 (en) | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
| WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| FR2772272B1 (fr) | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| CN100379407C (zh) | 1997-12-19 | 2008-04-09 | 史密丝克莱恩比彻姆公司 | 生产咀嚼分散片的方法 |
| US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
| US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
| US6706700B2 (en) | 1999-12-02 | 2004-03-16 | Akzo-Nobel, N.V. | 14β,15β-methylene-17α-hydroxymethyl-androgens |
| KR100747965B1 (ko) | 2000-01-18 | 2007-08-08 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 호르몬 보충 요법용 드로스피렌온 |
| US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| DE60217324T2 (de) * | 2001-05-18 | 2007-04-26 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung für die hormonersatztherapie |
| DE60223795T2 (de) | 2001-05-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption |
| ES2337129T3 (es) | 2001-05-23 | 2010-04-21 | Pantarhei Bioscience B.V. | Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal. |
| US20020193356A1 (en) | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
| ES2208518T3 (es) | 2001-05-23 | 2004-06-16 | Pantarhei Bioscience B.V. | Medio y metodo anticonceptivo hormonal. |
| EP1389117A1 (en) | 2001-05-23 | 2004-02-18 | Pantarhei Bioscience B.V. | Means and method for hormonal contraception |
| WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| CA2467222C (en) | 2001-11-15 | 2010-06-08 | Herman Jan Tijmen Coelingh Bennink | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| CA2476940C (en) | 2002-02-21 | 2011-11-01 | Herman Jan Tijmen Coelingh Bennink | Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12 |
| US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| US7923440B2 (en) | 2002-06-11 | 2011-04-12 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| CA2489270C (en) | 2002-06-11 | 2012-08-07 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| EP1526856B1 (en) | 2002-07-12 | 2008-01-02 | Pantarhei Bioscience B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| PL374762A1 (en) | 2002-08-28 | 2005-10-31 | Robert Casper | Estrogen replacement regimen |
| DE60318092T2 (de) | 2002-10-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung |
| JP2006508945A (ja) | 2002-11-05 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | 抗−アルドステロン性プロゲスチンを用いての心血管保護 |
| CN100343269C (zh) | 2002-11-08 | 2007-10-17 | 潘塔希生物科学股份有限公司 | 通过雌酮衍生的甾体化合物合成雌四醇 |
| EP1617859A1 (en) * | 2003-04-30 | 2006-01-25 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| PL1624878T3 (pl) | 2003-05-22 | 2007-01-31 | Pantarhei Bioscience Bv | Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu |
| AU2004275469B2 (en) | 2003-09-29 | 2010-07-15 | Novo Nordisk Health Care Ag | HRT formulations |
| ES2933479T3 (es) | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
| JP3841804B2 (ja) | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
| EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| US20050113350A1 (en) | 2003-11-26 | 2005-05-26 | Bernd Duesterberg | Extended use combination comprising estrogens and progestins |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
| DK1755562T3 (da) | 2004-05-28 | 2013-12-16 | Richter Gedeon Nyrt | Kontraceptivum, som indeholder folsyre |
| DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| ATE424814T1 (de) | 2004-07-01 | 2009-03-15 | Lek Pharmaceuticals | Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| WO2006082501A2 (en) | 2005-02-03 | 2006-08-10 | Nycomed Pharma As | Fast wet-massing method for the preparation of calcium-containing compositions |
| JP5004236B2 (ja) | 2005-02-09 | 2012-08-22 | キッセイ薬品工業株式会社 | 口腔内崩壊錠 |
| IS7724A (is) | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| AU2006251154B2 (en) | 2005-05-26 | 2012-06-28 | Solvay Pharmaceuticals Gmbh | 17beta-HSD1 and STS inhibitors |
| WO2007002823A2 (en) | 2005-06-29 | 2007-01-04 | Wyeth | Formulations of conjugated estrogens and bazedoxifene |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| CA2636638C (en) | 2006-01-09 | 2014-02-18 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
| DE602007009358D1 (de) | 2006-01-09 | 2010-11-04 | Pantarhei Bioscience Bv | Verfahren zur behandlung einer akuten gefässerkrankung |
| MX2008011074A (es) | 2006-03-02 | 2008-09-10 | Warner Chilcott Co Inc | Metodo anticonceptivo oral multifasico de ciclo prolongado. |
| CA2649361C (en) | 2006-06-08 | 2014-09-30 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
| US20070286819A1 (en) * | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
| US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| KR20090029824A (ko) | 2006-07-06 | 2009-03-23 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임용 및 선천성 기형 위험 예방용 제약 제제 |
| CL2007003429A1 (es) | 2006-11-29 | 2008-04-11 | Wyeth Corp | Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti |
| RU2465907C2 (ru) | 2006-12-20 | 2012-11-10 | Тева Вимен'С Хелс, Инк. | Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм |
| WO2008085038A2 (en) | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| KR20090104862A (ko) | 2007-01-12 | 2009-10-06 | 와이어쓰 | 정제내 정제 조성물 |
| EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| WO2008156365A1 (en) | 2007-06-21 | 2008-12-24 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| CN101778635A (zh) | 2007-07-19 | 2010-07-14 | 潘塔希生物科学股份有限公司 | 妊娠高血压病变或胎儿生长迟缓的治疗或预防 |
| FR2920311B1 (fr) | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
| JP5399749B2 (ja) | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
| DK2262486T3 (da) | 2008-08-01 | 2013-03-25 | Krka Tovarna Zdravil D D Novo Mesto | Quetiapin sammensætning |
| WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| CN101780073B (zh) | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | 非布司他分散片药物及其制备方法 |
| US8303868B2 (en) | 2009-01-26 | 2012-11-06 | Shin-Etsu Chemical Co., Ltd. | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose |
| DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
| EP2410995A1 (en) | 2009-03-26 | 2012-02-01 | Royal College of Surgeons in Ireland | Orodispersible tablets |
| ITMI20091109A1 (it) | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
| WO2010149273A1 (de) | 2009-06-23 | 2010-12-29 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung zur notfallempfängnisverhütung |
| CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
| US8901185B2 (en) | 2010-04-12 | 2014-12-02 | Universite Claude Bernard Lyon I | Hybrid organic-inorganic material constituted by a silica network having photochromic agents and optical power limiting agents as a doping agent in the material |
| KR20130097073A (ko) | 2010-04-15 | 2013-09-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 초저-용량의 ｈｒｔ용 고체 경구 투여 형태 |
| EP2399904A1 (en) | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| WO2012075455A2 (en) | 2010-12-02 | 2012-06-07 | Aptalis Pharmatech, Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
| JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
| HUE031809T2 (en) | 2011-06-01 | 2017-08-28 | Estetra Sprl | Process for the preparation of estetrol intermediates |
| AU2012264602B2 (en) | 2011-06-01 | 2017-03-09 | Estetra Srl | Process for the production of estetrol intermediates |
| CL2013003435A1 (es) | 2011-06-01 | 2014-08-01 | Estetra Sprl | Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol. |
| CN103796643B (zh) | 2011-07-19 | 2016-06-22 | 潘塔希生物科学股份有限公司 | 含有脱氢表雄酮(dhea)的片剂 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| BR112014003113A2 (pt) | 2011-08-11 | 2017-03-14 | Estetra Sprl | método de contracepção de emergência em uma fêmea mamífero |
| NZ620897A (en) | 2011-09-16 | 2016-07-29 | Ferring Bv | A fast dissolving pharmaceutical composition |
| HUE028963T2 (en) | 2011-10-07 | 2017-01-30 | Estetra Sprl | Process for the preparation of estetrol |
| WO2013090117A1 (en) | 2011-12-13 | 2013-06-20 | Arstat, Inc. | A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
| US9238265B2 (en) | 2012-09-27 | 2016-01-19 | General Electric Company | Backstrike protection during machining of cooling features |
| WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
| JP6126456B2 (ja) | 2013-05-17 | 2017-05-10 | 東和薬品株式会社 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
| US20140341326A1 (en) | 2013-05-20 | 2014-11-20 | Qualcomm Incorporated | Channel estimation with discontinuous pilot signals |
| US9161941B2 (en) | 2013-05-21 | 2015-10-20 | Predictive Therapeutics, LLC | Therapeutic and method of use |
| US9988417B2 (en) | 2013-09-18 | 2018-06-05 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| US12274276B2 (en) | 2013-10-03 | 2025-04-15 | Altria Client Services Llc | Dissolvable-chewable tablet |
| AU2014359194B2 (en) * | 2013-12-04 | 2020-02-06 | Galderma Research & Development | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology |
| BR112016013502B1 (pt) | 2013-12-12 | 2021-05-11 | Estetra Sprl | unidade de dosagem farmacêutica sólida que desintegra oralmente contendo um componente de estetrol, método para a preparação da unidade de dosagem sólida e uso de grânulos consistindo em um componente de estetrol |
| WO2016023009A1 (en) | 2014-08-07 | 2016-02-11 | Wake Forest University Health Sciences | Compositions and methods for clearing a biological sample |
| US9962395B2 (en) | 2014-09-29 | 2018-05-08 | The Regents Of The University Of California | Compositions and methods for maintaining cognitive function |
| EP3297634A1 (en) | 2015-05-18 | 2018-03-28 | Agile Therapeutics, Inc. | Contraceptive compositions and methods for improved efficacy and modulation of side effects |
| EP3106148B1 (en) * | 2015-06-18 | 2018-03-14 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| BR112017027229B1 (pt) | 2015-06-18 | 2023-12-05 | Estetra Sprl | Grânulos contendo estetrol secos, unidade de dosagem compreendendo grânulos, processo de preparação e seus usos |
| MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| DK3310346T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
| SI3313408T1 (sl) | 2015-06-23 | 2024-04-30 | Laboratorios Leon Farma Sa | Kontraceptiv na osnovi drospirenona za pacientko s prekomerno težo |
| US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
| CN115429806A (zh) | 2018-02-07 | 2022-12-06 | 埃斯特拉有限责任公司 | 具有降低的心血管作用的避孕组合物 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| US10929286B2 (en) | 2018-06-29 | 2021-02-23 | Seagate Technology Llc | Arbitrated management of a shared non-volatile memory resource |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
-
2016
- 2016-06-17 BR BR112017027229-6A patent/BR112017027229B1/pt active IP Right Grant
- 2016-06-17 EA EA202090984A patent/EA202090984A1/ru unknown
- 2016-06-17 MX MX2017016274A patent/MX384904B/es unknown
- 2016-06-17 HU HUE16733341A patent/HUE049232T2/hu unknown
- 2016-06-17 AU AU2016280858A patent/AU2016280858B2/en active Active
- 2016-06-17 CN CN202310318485.8A patent/CN116077455A/zh active Pending
- 2016-06-17 DK DK16733341.8T patent/DK3310333T3/da active
- 2016-06-17 CN CN201680035626.3A patent/CN107787224A/zh active Pending
- 2016-06-17 HR HRP20200850TT patent/HRP20200850T1/hr unknown
- 2016-06-17 ES ES16733341T patent/ES2800774T3/es active Active
- 2016-06-17 MY MYPI2017001863A patent/MY186164A/en unknown
- 2016-06-17 HU HUE20171407A patent/HUE057741T2/hu unknown
- 2016-06-17 PL PL20171407T patent/PL3701944T3/pl unknown
- 2016-06-17 US US15/737,227 patent/US11147771B2/en active Active
- 2016-06-17 SI SI201631422T patent/SI3701944T1/sl unknown
- 2016-06-17 MA MA45972A patent/MA45972B1/fr unknown
- 2016-06-17 DK DK20171407.8T patent/DK3701944T3/da active
- 2016-06-17 GE GEAP201614676A patent/GEP20217243B/en unknown
- 2016-06-17 MD MDE20180407T patent/MD3310333T2/ro unknown
- 2016-06-17 EP EP20171407.8A patent/EP3701944B1/en active Active
- 2016-06-17 PT PT167333418T patent/PT3310333T/pt unknown
- 2016-06-17 EA EA201890085A patent/EA035687B1/ru unknown
- 2016-06-17 LT LTEP20171407.8T patent/LT3701944T/lt unknown
- 2016-06-17 LT LTEP16733341.8T patent/LT3310333T/lt unknown
- 2016-06-17 EP EP16733341.8A patent/EP3310333B1/en active Active
- 2016-06-17 KR KR1020187001722A patent/KR102662025B1/ko active Active
- 2016-06-17 KR KR1020237017164A patent/KR102735893B1/ko active Active
- 2016-06-17 PE PE2022002730A patent/PE20231714A1/es unknown
- 2016-06-17 RS RS20200563A patent/RS60252B1/sr unknown
- 2016-06-17 ES ES20171407T patent/ES2906228T3/es active Active
- 2016-06-17 JP JP2017564402A patent/JP6866560B2/ja active Active
- 2016-06-17 CA CA2988495A patent/CA2988495C/en active Active
- 2016-06-17 NZ NZ737945A patent/NZ737945A/en unknown
- 2016-06-17 PT PT201714078T patent/PT3701944T/pt unknown
- 2016-06-17 NZ NZ776452A patent/NZ776452A/en unknown
- 2016-06-17 RS RS20211590A patent/RS62844B1/sr unknown
- 2016-06-17 CU CU2017000161A patent/CU24504B1/es unknown
- 2016-06-17 HR HRP20211968TT patent/HRP20211968T1/hr unknown
- 2016-06-17 WO PCT/EP2016/064065 patent/WO2016203006A1/en not_active Ceased
- 2016-06-17 CR CR20180041A patent/CR20180041A/es unknown
- 2016-06-17 SM SM20220102T patent/SMT202200102T1/it unknown
- 2016-06-17 UA UAA201800476A patent/UA123099C2/uk unknown
- 2016-06-17 ME MEP-2020-96A patent/ME03728B/me unknown
- 2016-06-17 SI SI201630752T patent/SI3310333T1/sl unknown
- 2016-06-17 SM SM20200251T patent/SMT202000251T1/it unknown
- 2016-06-17 PE PE2017002732A patent/PE20180522A1/es unknown
- 2016-06-17 TN TNP/2017/000497A patent/TN2017000497A1/en unknown
- 2016-06-17 PL PL16733341T patent/PL3310333T3/pl unknown
-
2017
- 2017-12-06 ZA ZA2017/08286A patent/ZA201708286B/en unknown
- 2017-12-11 CO CONC2017/0012670A patent/CO2017012670A2/es unknown
- 2017-12-11 DO DO2017000294A patent/DOP2017000294A/es unknown
- 2017-12-12 IL IL256282A patent/IL256282B/en unknown
- 2017-12-14 CL CL2017003209A patent/CL2017003209A1/es unknown
- 2017-12-15 PH PH12017502326A patent/PH12017502326B1/en unknown
- 2017-12-15 SV SV2017005596A patent/SV2017005596A/es unknown
- 2017-12-29 EC ECIEPI201785659A patent/ECSP17085659A/es unknown
-
2020
- 2020-05-22 CY CY20201100468T patent/CY1123006T1/el unknown
-
2021
- 2021-02-16 JP JP2021022465A patent/JP7140355B2/ja active Active
- 2021-05-21 AU AU2021203265A patent/AU2021203265B2/en active Active
- 2021-10-18 US US17/504,087 patent/US11964055B2/en active Active
- 2021-12-22 CY CY20211101127T patent/CY1124878T1/el unknown
-
2022
- 2022-06-06 LT LTPA2022508C patent/LTC3701944I2/lt unknown
- 2022-06-07 NO NO2022020C patent/NO2022020I1/no unknown
- 2022-06-07 HU HUS2200027C patent/HUS2200027I1/hu unknown
- 2022-12-05 AU AU2022283615A patent/AU2022283615B2/en active Active
-
2023
- 2023-03-06 ZA ZA2023/03338A patent/ZA202303338B/en unknown
- 2023-05-12 US US18/196,617 patent/US11793760B2/en active Active
-
2024
- 2024-02-23 AU AU2024201228A patent/AU2024201228B2/en active Active
- 2024-03-29 US US18/621,501 patent/US12427114B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012670A2 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| CO2017012766A2 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| MX375187B (es) | Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras. | |
| CL2015002702A1 (es) | Composiciones farmacéuticas micronizadas. | |
| MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| MX380536B (es) | Composicion y metodo para tratar la enfermedad de chagas. | |
| CO2017000354A2 (es) | Desmopresina estabilizada | |
| CO2019008347A2 (es) | Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla |